Chemotherapy and Immunotherapy in Extensive-Stage Small-Cell Lung Cancer With Thoracic Radiotherapy

Summary

This is a prospective, multi-centre, single arm, phase 2, open label clinical trial of patients with untreated extensive-stage small-cell lung cancer (ES-SCLC) suitable for first-line platinum-based chemotherapy. The aim of the trial is to assess safety, feasibility and describe efficacy of the addition of concurrent thoracic radiotherapy to usual treatment of chemotherapy and immunotherapy (durvalumab) in patients with ES-SCLC.

Timeline

Start

2022-01-01

Primary completion

2027-09-30

Completion

2028-02-28

Publications

• Parakh S, Gee H, Lim A, Vinod S, Wheeler C, Rooney B, Montgomery R, Harden S, Moore M, Lehman M, Bettington C, Moodie T, Barber J, Schmidt L, Dizon J, Leigh L, Oldmeadow C, Mitchell P, Hau E. Platinum and etoposide chemotherapy, durvalumab with thoracic radiotherapy in the first-line treatment of patients with extensive-stage small-cell lung cancer: CHEST-RT (TROG 20.01) Trial - protocol for a phase II study. BMJ Open. 2025 Jul 7;15(7):e101571. doi: 10.1136/bmjopen-2025-101571.

Drugs

Indications